ASPP2 promotes cell apoptosis in cervical cancer through inhibiting autophagy

Jiang,Feiyun; Bian,Ganxia; Li,Jiehua

doi:10.3892/etm.2022.11662

ASPP2 promotes cell apoptosis in cervical cancer through inhibiting autophagy

Authors:
- Feiyun Jiang
- Ganxia Bian
- Jiehua Li
View Affiliations

Affiliations: Department of Gynecology, Wuhu Hospital, East China Normal University (The Second People's Hospital of Wuhu), Wuhu, Anhui 241000, P.R. China, Department of Obstetrics and Gynecology, Yancheng First People's Hospital, Yancheng, Jiangsu 224006, P.R. China
Published online on: October 20, 2022 https://doi.org/10.3892/etm.2022.11662
Article Number: 726
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is a common tumor of the reproductive system; however, to the best of the authors' knowledge, the regulation and underlying mechanism of p53 apoptosis‑stimulating protein 2 (ASPP2) in cervical cancer has yet to be elucidated. Therefore, the present study aimed to explore the role of ASPP2 in cervical cancer. Tumor tissues were collected for the detection of ASPP2 expression. Experiments wherein ASPP2 was overexpressed were designed to upregulate the expression of ASPP2. The levels of autophagy were subsequently assessed by examining LC3B level via immunofluorescence. Cell Counting Kit‑8 assay was then performed to estimate the level of cell proliferation. The cell proliferation level was also measured by EdU staining, and TUNEL assay was used to detect the level of apoptosis. The expression levels of ASPP2, Beclin1 and associated proteins were detected using reverse transcription‑quantitative PCR and western blotting analyses. ASPP2 was observed to be markedly reduced in patients with cervical cancer and in cervical cancer cell lines. Overexpression of ASPP2 was found to suppress the expression of Beclin1, and autophagy was also inhibited in cervical cancer cells. Overexpression of ASPP2 also inhibited cell proliferation and promoted apoptosis of cervical cancer cells via the inhibition of autophagy. Additionally, overexpression of ASPP2 was shown to enhance the TNF‑related apoptosis‑inducing ligand‑induced apoptosis of cervical cancer cells via inhibiting autophagy. Taken together, the results of the present study have shown that ASPP2 exerted antitumor effect in cervical cancer by inhibiting cell proliferation and promoting apoptosis partly through inhibiting autophagy. These findings may be useful for the provision of potential targets for cervical cancer therapy.

View Figures

View References

1	Chen G, Zhang M, Zhu J, Chen F, Yu D, Zhang A, He J, Hua W and Duan P: Common genetic variants in pre-microRNAs are associated with cervical cancer susceptibility in southern Chinese women. J Cancer. 11:2133–2138. 2020.PubMed/NCBI View Article : Google Scholar
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
3	Gardner AB, Charo LM, Mann AK, Kapp DS, Eskander RN and Chan JK: Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: Most common locations and outcomes. Clin Exp Metastasis. 37:107–113. 2020.PubMed/NCBI View Article : Google Scholar
4	Printz C: Rethinking a common surgery technique for early cervical cancer: Experts are reconsidering the use of minimally invasive radical hysterectomy as a treatment for early cervical cancer after multiple studies found that patients who undergo the procedure by either laparoscopy or robotic surgery have poorer outcomes. Cancer. 125:3485–3487. 2019.PubMed/NCBI View Article : Google Scholar
5	Mendez LC, Moraes FY, Castilho MS, Louie AV and Qu XM: Lives and economic loss in brazil due to lack of radiotherapy access in cervical cancer: A cost-effectiveness analysis. Clin Oncol (R Coll Radiol). 31:e143–e148. 2019.PubMed/NCBI View Article : Google Scholar
6	You KY, Peng HH, Jiang YH, Bi ZF and Qiu XS: Selective use of concurrent chemotherapy in elderly cervical cancer patients treated with definitive radiotherapy: Experience from two institutions. Cancer Manag Res. 11:4815–4823. 2019.PubMed/NCBI View Article : Google Scholar
7	Vives V, Slee EA and Lu X: ASPP2: A gene that controls life and death in vivo. Cell Cycle. 5:2187–2190. 2006.PubMed/NCBI View Article : Google Scholar
8	Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T and Lu X: ASPP1 and ASPP2: Common activators of p53 family members. Mol Cell Biol. 24:1341–1350. 2004.PubMed/NCBI View Article : Google Scholar
9	Konno T, Kohno T, Okada T, Shimada H, Satohisa S, Kikuchi S, Saito T and Kojima T: ASPP2 suppression promotes malignancy via LSR and YAP in human endometrial cancer. Histochem Cell Biol. 154:197–213. 2020.PubMed/NCBI View Article : Google Scholar
10	Yang T, Gao Y, Liu D, Wang Y, Wu J, Liu X, Shi Y and Chen D: ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma. Biochem Biophys Res Commun. 508:769–774. 2019.PubMed/NCBI View Article : Google Scholar
11	Liang B, Chen R, Song S, Wang H, Sun G, Yang H, Jing W, Zhou X, Fu Z, Huang G and Zhao J: ASPP2 inhibits tumor growth by repressing the mevalonate pathway in hepatocellular carcinoma. Cell Death Dis. 10(830)2019.PubMed/NCBI View Article : Google Scholar
12	Wu T, Song H, Xie D, Zhao B, Xu H, Wu C, Hua K, Deng Y, Ji C, Hu J and Fang L: Silencing of ASPP2 promotes the proliferation, migration and invasion of triple-negative breast cancer cells via the PI3K/AKT pathway. Int J Oncol. 52:2001–2010. 2018.PubMed/NCBI View Article : Google Scholar
13	Xie F, Jia L, Lin M, Shi Y, Yin J, Liu Y, Chen D and Meng Q: ASPP2 attenuates triglycerides to protect against hepatocyte injury by reducing autophagy in a cell and mouse model of non-alcoholic fatty liver disease. J Cell Mol Med. 19:155–164. 2015.PubMed/NCBI View Article : Google Scholar
14	Huang W, Li X and Cai L: Effects of ASPP2 on proliferation and apoptosis of malignant spinal tumor cells. Int J Clin Exp Pathol. 10:8023–8030. 2017.PubMed/NCBI
15	Wang X, Yu M, Zhao K, He M, Ge W, Sun Y, Wang Y, Sun H and Hu Y: Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2. Cell Death Dis. 7(e2517)2016.PubMed/NCBI View Article : Google Scholar
16	Chen R, Wang H, Liang B, Liu G, Tang M, Jia R, Fan X, Jing W, Zhou X, Wang H, et al: Downregulation of ASPP2 improves hepatocellular carcinoma cells survival via promoting BECN1-dependent autophagy initiation. Cell Death Dis. 7(e2512)2016.PubMed/NCBI View Article : Google Scholar
17	Shi Y, Han Y, Xie F, Wang A, Feng X, Li N, Guo H and Chen D: ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy. J Cell Mol Med. 19:535–543. 2015.PubMed/NCBI View Article : Google Scholar
18	Song B, Bian Q, Zhang YJ, Shao CH, Li G, Liu AA, Jing W, Liu R, Zhou YQ, Jin G and Hu XG: Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation. Mol Cancer. 14(177)2015.PubMed/NCBI View Article : Google Scholar
19	Gund R and Christiano AM: Impaired autophagy promotes hair loss in the C3H/HeJ mouse model of alopecia areata. Autophagy: Jun 2, 2022 (Epub ahead of print).
20	Follo C, Cheng Y, Richards WG, Bueno R and Broaddus VC: Autophagy facilitates the release of immunogenic signals following chemotherapy in 3D models of mesothelioma. Mol Carcinog. 58:1754–1769. 2019.PubMed/NCBI View Article : Google Scholar
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
22	Zinnah KMA and Park SY: Duloxetine enhances TRAIL-mediated apoptosis via AMPK-mediated inhibition of autophagy flux in lung cancer cells. Anticancer Res. 39:6621–6633. 2019.PubMed/NCBI View Article : Google Scholar
23	Hailu HE, Mondul AM, Rozek LS and Geleta T: Descriptive Epidemiology of breast and gynecological cancers among patients attending Saint Paul's hospital millennium medical college, Ethiopia. PLoS One. 15(e0230625)2020.PubMed/NCBI View Article : Google Scholar
24	Schittenhelm MM, Walter B, Tsintari V, Federmann B, Bajrami Saipi M, Akmut F, Illing B, Mau-Holzmann U, Fend F, Lopez CD and Kampa-Schittenhelm KM: Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia. EBioMedicine. 42:340–351. 2019.PubMed/NCBI View Article : Google Scholar
25	Schittenhelm MM, Illing B, Ahmut F, Rasp KH, Blumenstock G, Döhner K, Lopez CD and Kampa-Schittenhelm KM: Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure. PLoS One. 8(e80193)2013.PubMed/NCBI View Article : Google Scholar
26	Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999.PubMed/NCBI View Article : Google Scholar
27	Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al: Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 112:1809–1820. 2003.PubMed/NCBI View Article : Google Scholar
28	Yue Z, Jin S, Yang C, Levine AJ and Heintz N: Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA. 100:15077–15082. 2003.PubMed/NCBI View Article : Google Scholar
29	Hartung F, Krüwel T, Shi X, Pfizenmaier K, Kontermann R, Chames P, Alves F and Pardo LA: A novel anti-Kv10.1 nanobody fused to single-chain TRAIL enhances apoptosis induction in cancer cells. Front Pharmacol. 11(686)2020.PubMed/NCBI View Article : Google Scholar
30	Cao Y, Kong S, Xin Y, Meng Y, Shang S and Qi Y: Lestaurtinib potentiates TRAIL-induced apoptosis in glioma via CHOP-dependent DR5 induction. J Cell Mol Med. 24:7829–7840. 2020.PubMed/NCBI View Article : Google Scholar
31	Saparbay J, Tanaka Y, Tanimine N, Ohira M and Ohdan H: Everolimus enhances TRAIL-mediated anti-tumor activity of liver resident natural killer cells in mice. Transpl Int. 33:229–243. 2020.PubMed/NCBI View Article : Google Scholar
32	Cao TM and King MR: Supercharged eGFP-TRAIL decorated NETs to ensnare and kill disseminated tumor cells. Cell Mol Bioeng. 13:359–367. 2020.PubMed/NCBI View Article : Google Scholar
33	Zhuo FF, Zhang C, Zhang H, Xia Y, Xue GM, Yang L and Kong LY: Chrysanthemulide A induces apoptosis through DR5 upregulation via JNK-mediated autophagosome accumulation in human osteosarcoma cells. J Cell Physiol. 234:13191–13208. 2019.PubMed/NCBI View Article : Google Scholar